Multicenter, Randomized, Non-comparative, Open-label Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.

Trial Profile

Multicenter, Randomized, Non-comparative, Open-label Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Trabectedin (Primary) ; Carboplatin
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2016 Data from this trial presented at 16th Biennial International Gynecologic Cancer Society Meeting (IGCS), as per PharmaMar media release.
    • 22 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2017.
    • 22 Jun 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top